Initiate clinical studies for PBFT02 and PBKR03
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Checked
- 24 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Passage Bio anticipates the start of both clinical programs in the first half of 2021.”
What we found
Evidence strength A What the grades mean
The company failed to initiate clinical studies for PBFT02 and PBKR03 by the first half of 2021, subsequently pushing the initiation dates to the third and then fourth quarters of 2021.
-
A Passage Bio, Inc. 8-K filed 2021-08-05
“Global Phase 1/2 clinical trials for both PBFT02 and PBKR03 on track to dose first patients in third quarter of 2021” ✓ confirmed on the page
-
A Passage Bio, Inc. 10-Q filed 2021-11-04
“We expect to initiate our GALax-C Trial in the fourth quarter of 2021” ✓ confirmed on the page
-
A Passage Bio, Inc. 10-Q filed 2021-11-04
“We expect to initiate our upliFT-D Trial in the fourth quarter of 2021” ✓ confirmed on the page
Market reaction: the shares moved +2.7% against the S&P 500 over the three sessions around the disclosure (4 Aug 2021 to 9 Aug 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Clinical studies for PBFT02 and PBKR03
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Passage Bio, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-PASG-021451 · Corrections policy